These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 21799030)

  • 1. Chromogranin A restricts drug penetration and limits the ability of NGR-TNF to enhance chemotherapeutic efficacy.
    Dondossola E; Gasparri AM; Colombo B; Sacchi A; Curnis F; Corti A
    Cancer Res; 2011 Sep; 71(17):5881-90. PubMed ID: 21799030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration.
    Curnis F; Sacchi A; Corti A
    J Clin Invest; 2002 Aug; 110(4):475-82. PubMed ID: 12189241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromogranin A protects vessels against tumor necrosis factor alpha-induced vascular leakage.
    Ferrero E; Scabini S; Magni E; Foglieni C; Belloni D; Colombo B; Curnis F; Villa A; Ferrero ME; Corti A
    FASEB J; 2004 Mar; 18(3):554-6. PubMed ID: 14734634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin.
    Sacchi A; Gasparri A; Curnis F; Bellone M; Corti A
    Cancer Res; 2004 Oct; 64(19):7150-5. PubMed ID: 15466213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha.
    Crippa L; Gasparri A; Sacchi A; Ferrero E; Curnis F; Corti A
    Cancer Res; 2008 Feb; 68(4):1154-61. PubMed ID: 18281491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041).
    van Laarhoven HW; Fiedler W; Desar IM; van Asten JJ; Marréaud S; Lacombe D; Govaerts AS; Bogaerts J; Lasch P; Timmer-Bonte JN; Lambiase A; Bordignon C; Punt CJ; Heerschap A; van Herpen CM
    Clin Cancer Res; 2010 Feb; 16(4):1315-23. PubMed ID: 20145168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).
    Curnis F; Sacchi A; Borgna L; Magni F; Gasparri A; Corti A
    Nat Biotechnol; 2000 Nov; 18(11):1185-90. PubMed ID: 11062439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer.
    Bertilaccio MT; Grioni M; Sutherland BW; Degl'Innocenti E; Freschi M; Jachetti E; Greenberg NM; Corti A; Bellone M
    Prostate; 2008 Jul; 68(10):1105-15. PubMed ID: 18437689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells.
    Curnis F; Arrigoni G; Sacchi A; Fischetti L; Arap W; Pasqualini R; Corti A
    Cancer Res; 2002 Feb; 62(3):867-74. PubMed ID: 11830545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha.
    Sacchi A; Gasparri A; Gallo-Stampino C; Toma S; Curnis F; Corti A
    Clin Cancer Res; 2006 Jan; 12(1):175-82. PubMed ID: 16397040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs.
    Corti A; Ponzoni M
    Ann N Y Acad Sci; 2004 Dec; 1028():104-12. PubMed ID: 15650236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human tumor necrosis factor: an efficient agent for cancer treatment.
    Lejeune FJ; Rüegg C
    Bull Cancer; 2006 Aug; 93(8):E90-100. PubMed ID: 16935777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating chromogranin A reveals extra-articular involvement in patients with rheumatoid arthritis and curbs TNF-alpha-elicited endothelial activation.
    Di Comite G; Rossi CM; Marinosci A; Lolmede K; Baldissera E; Aiello P; Mueller RB; Herrmann M; Voll RE; Rovere-Querini P; Sabbadini MG; Corti A; Manfredi AA
    J Leukoc Biol; 2009 Jan; 85(1):81-7. PubMed ID: 18832606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects.
    van der Veen AH; de Wilt JH; Eggermont AM; van Tiel ST; Seynhaeve AL; ten Hagen TL
    Br J Cancer; 2000 Feb; 82(4):973-80. PubMed ID: 10732774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale for using TNF alpha and chemotherapy in regional therapy of melanoma.
    Lejeune F; Liénard D; Eggermont A; Schraffordt Koops H; Rosenkaimer F; Gérain J; Klaase J; Kroon B; Vanderveken J; Schmitz P
    J Cell Biochem; 1994 Sep; 56(1):52-61. PubMed ID: 7806592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
    Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
    Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
    Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
    Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A human melanoma xenograft in a nude rat responds to isolated limb perfusion with TNF plus melphalan.
    Bauer TW; Gutierrez M; Dudrick DJ; Li J; Blair IA; Menon C; Fraker DL
    Surgery; 2003 Apr; 133(4):420-8. PubMed ID: 12717360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromogranin A (CGA)-derived polypeptide (CGA
    Luo L; Liu S; Zhang D; Wei F; Gu N; Zeng Y; Chen X; Xu S; Liu S; Xiang T
    Peptides; 2020 Sep; 131():170297. PubMed ID: 32380199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The IL-6/sIL-6R treatment of a malignant melanoma cell line enhances susceptibility to TNF-alpha-induced apoptosis.
    Wagley Y; Yoo YC; Seo HG; Rhee MH; Kim TH; Kang KW; Nah SY; Oh JW
    Biochem Biophys Res Commun; 2007 Mar; 354(4):985-91. PubMed ID: 17274948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.